Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
IBA – Transparency Notification | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: GlobeNewswire - 28 May 2020 | Back to overview list |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, May 28, 2020, 17.30 Summary of the notification IBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, received a transparency notification dated May 19, 2020, from which it follows that, following the introduction of statutory thresholds on April 30, 2020, the University Catholique de Louvain, including the voting rights of its subsidiary Sopartec SA, now holds 2.71% of the voting rights in the company. It thus crossed upwards the 2% participation threshold. Content of the notification
Sopartec SA is a subsidiary of UCLouvain (100% minus one share).
Passive crossing following the introduction of the loyalty vote and new thresholds in the Issuer's articles of association. For further information, please contact: IBA Elodie Jaumain About IBA IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
Attachment |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2020 GlobeNewswire | Back to overview list |